The Vaccine Response and Immunotherapeutics (VRI) Scientific Working Group was added to the CFAR in 2021 to foster research related to vaccines and other immunotherapeutics for people living with HIV (PLWH). The SARS-CoV-2 pandemic has demonstrated the enormous public health impact of vaccination. As much of the scientific community pivoted to studying SARS-CoV-2 and vaccine development proceeded with unprecedented speed, HIV researchers at JHU recognized the importance of inclusion of PLWH in vaccine studies, as well as the potential implications of COVID-19 vaccinology to other vaccines, including HIV preventive and therapeutic vaccines. The immunosuppressive consequences of HIV on the effectiveness and durability of vaccine protection is not well characterized and is an important area of research. In addition to COVID vaccines, clinical research evaluating the durability and cellular immune responses to childhood and other adult vaccines is critical to determining if current vaccine schedules and recommendations are appropriate for PLWH. This SWG will focus on HIV and non-HIV vaccines and immunotherapeutics for PLWH to promote vaccine science education, foster research interest in vaccines and immunotherapeutics among early- and mid-level faculty, and coordinate with other SWGs to achieve these goals.